The efficacy of recombinant turkey herpesvirus vaccines targeting the H5 of highly pathogenic avian influenza virus from the 2014–2015 North American outbreak

• Published in: Vaccine Vol. 36; no. 1; pp. 84 - 90
• Main Authors: Balzli, Charles L., Bertran, Kateri, Lee, Dong-Hun, Killmaster, Lindsay, Pritchard, Nikki, Linz, Perry, Mebatsion, Teshome, Swayne, David E.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 02-01-2018; Elsevier Limited
• Subjects: Avian flu; Birds; Chicken; Chickens; Disease control; Effectiveness; Epidemics; Hemagglutinins; Highly pathogenic avian influenza; Influenza; Inserts; Outbreaks; Pandemics; Poultry; Recombinant turkey herpesvirus; Strains (organisms); Survival; Vaccine; Vaccine efficacy; Vaccines; Viruses; United States > US; Recombinant turkey herpesvirus; Vaccine; Highly pathogenic avian influenza; Chicken; Poultry
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2017.11.026

The outbreak of highly pathogenic avian influenza virus in North American poultry during 2014 and 2015 demonstrated the devastating effects of the disease and highlighted the need for effective emergency vaccine prevention and control strategies targeted at currently circulating strains. This study evaluated the efficacy of experimental recombinant turkey herpesvirus vector vaccines with three different inserts targeting the hemagglutinin gene of an isolate from the recent North American influenza outbreak. White leghorn chickens were vaccinated at one day of age and challenged with A/Turkey/Minnesota/12582/2015 H5N2 at 4 weeks of age. Birds were analyzed for survival, viral shedding at two and four days after infection, and specific antibody prior to challenge and from surviving birds. The three experimental vaccines demonstrated 100%, 45% and 15% survival with the most effective vaccine significantly reducing oral and cloacal viral shedding compared to all other groups and generated specific antibody prior to challenge with highly pathogenic avian influenza virus. More studies are needed using diverse H5Nx highly pathogenic virus isolates to fully determine the breadth of coverage against possible exposure strains, as well as possible impact of maternally derived antibody on protection and vaccine efficacy.